Integrative proteogenomics study identifies the indirect effect of circulating

proteins on 8 diseases via telomere length

Shifang Li, Meijiao Gong

Laboratory of Immunology and Vaccinology, FARAH, ULiège, Liège 4000, Belgium.

Correspondence:

Shifang Li, fruceslee@gmail.com

Laboratory of Immunology and Vaccinology, FARAH, ULiège, Liège 4000, Belgium

Abstract

Growing evidence has revealed the associations between telomere length and

diseases; however, the mechanisms behind these links are not fully understood. In this

study, by applying proteome-wide Mendelian randomisation (MR), multiple

sensitivity analyses, colocalization, single-cell RNA-sequencing, and mediation

analysis, the potential mechanisms that link 4,907 plasma proteins, telomere length,

and 8 diseases were identified. Following MR analysis for the effects of plasma

protein levels on telomere length, 34 proteins were found to be causally related to

telomere length. Among these, 8 proteins (PSMB4, PARP1, GDI2, MAX, GMPR2,

ARPC1B, ATOX1, and NUDT5) were found to be well colocalized with telomere

length (posterior probability >80%). 21 mediation pairs were revealed for the indirect

effect of circulating proteins on 8 diseases via telomere length. Furthermore, 35

proteins, including CD8A, were found to be influenced by telomere length among

4,907 proteins. No significant mediation pairs for circulating proteins that mediate the

effects of telomere length on disease have been identified. Overall, our study provided

insights into understanding the biology of telomeres and prioritized the identified

proteins as prospective intervention targets for the disease.

Introduction

Telomeres are 6-nucleotide repeats that are found at the ends of chromosomes

and are normally reduced as cells replicate and age. When telomeres reach a critical

length, cells enter senescence; thus, telomere shortening and malfunction are one of

the major characteristics of aging [1-2]. At the population level, there is significant

individual variation in mean telomere length (TL), which is typically assessed in

leukocytes but also in other tissues (eg., testis and cerebellum) [2-3]. Based on the

findings of epidemiological studies and Mendelian randomisation (MR) analyses,

researchers found out that several diseases, including melanoma, prostate cancer,

thyroid, uterine fibroid, multiple sclerosis, idiopathic pulmonary fibrosis (IPF),

coronary artery disease, and hypothyroidism are associated with telomere dysfunction;

however, the underlying mechanism between these associations is not fully

understood [3-8]. Identifying circulating proteins that mediate these associations or

determining the indirect influence of circulating proteins on diseases via TL is an

approach for disentangling this association. As circulating proteins in the blood may

be evaluated and, in some cases, manipulated, identifying related proteins may

provide insights into developing probable therapeutic targets [9].

MR is a classical approach in genetic epidemiology research that employs single

nucleotide polymorphisms (SNPs) related to the exposure variable under inquiry.

Using genetic polymorphisms randomly assigned at conception as an instrumental

variable (IV) for exposure, it is feasible to obtain estimates that are less susceptible to

the influence of environmental confounders and reverse causation [10-11].

Researchers are currently using this strategy to uncover therapies for various diseases,

including stroke, idiopathic pulmonary fibrosis (IPF), COVID-19, and ischemic heart

disease [9,12-14]. In addition, by performing MR and mediation analysis, Yoshiji *et al*.

have discovered nephronectin as an actionable mediator of the effect of body mass

index (BMI) on COVID-19 and COL6A3 as a mediator of the effect of obesity on

coronary artery disease [9,15]. Similarly, Chen *et al*. demonstrated that BMI, white

matter hyperintensity, and atrial fibrillation appear to mediate the TFPI, IL6RA, and

TMPRSS5 correlations with stroke [13]. The findings from these studies suggest that

an MR-based strategy represents an intriguing strategy for illuminating the potential

mechanisms between risk factors and disease.

In this study, we utilized proteome-wide MR using large-scale GWASs of plasma

protein, multiple sensitivity analyses, colocalization, single-cell RNA-sequencing

(scRNA-seq) analysis, and mediation analysis to identify the indirect effect of

circulating proteins on 8 diseases via TL and uncover circulating proteins mediating

the effects of TL on disease.

Methods

Data source for MR analysis

For MR analysis, publicly available GWAS summary data were applied. We selected the most complete GWAS for plasma proteins, which includes genome-wide associations of genetic variants for 4,907 circulating proteins in 35,559 Icelanders [16]. Prostate cancer (access ID: GCST90274714), uterine fibroids (access ID: GCST009158), hypothyroidism (access ID: GCST90204167), coronary artery disease (access ID: GCST005194), melanoma (access ID: GCST90011809), and thyroid cancer (access ID: GCST90011813) summary statistics were retrieved from the GWAS Catalog (https://www.ebi.ac.uk/gwas/). Prostate cancer included 122,188 cases and 604,640 controls of European ancestry [17], uterine fibroids comprised 20,406 cases and 223,918 controls of European ancestry [18], hypothyroidism included 51,194 cases and 443,383 controls of European ancestry [19], coronary artery disease comprised 34,541 cases and 261,984 controls of European ancestry [20], melanoma included 6,777 cases and 410,350 controls of European ancestry [21], and thyroid cancer included 762 cases and 410,350 controls of European ancestry [21]. The GWAS summary statistics for multiple sclerosis (access ID: ieu-b-18) [22], TL (access ID: ieu-b-4879) [8], and 102 CD8+ T cells subpopulations [23] (**Supplementary Table 1**) were downloaded from the ieu open gwas project (https://gwas.mrcieu.ac.uk/datasets/). The summary statistics of the large GWAS of IPF were applied from https://github.com/genomicsITER/PFgenetics [24]. Details of the included GWASs are summarized in **Supplementary Table 1**.

IVs selection

To satisfy the MR assumptions, the SNPs chosen as IVs had to show strong associations with exposure. To identify SNPs strongly linked to all symptoms, a genome-wide significance criterion of $p<$5e-08 was utilized. SNPs in the MHC region were removed as well in the case of the complex linkage disequilibrium (LD) structure of the MHC locus. To address bias caused by LD, we implemented SNP clumping with parameters kb=10,000 and r^2=0.001, as described previously [25].

Furthermore, we removed palindrome SNPs and used the F-statistic to measure the

strength of each SNP. SNPs with F-statistics greater than 10 were deemed sufficiently

powerful to serve as IVs for the trait.

MR and colocalization analysis

The MR analysis was carried out as previously described [25]. In brief, the

inverse-variance weighting approach (IVs≥2) and Wald ratio (IV=1) were chosen as

the primary analysis methods in the present study. Sensitivity analyses were

conducted to ensure the robustness of the findings and to resolve any potential

breaches of the MR assumptions. Cochran's Q test was employed to evaluate SNP

heterogeneity in both the IVW and MR Egger methods. In a heterogeneity test, I^2

statistics were estimated using the "Isq()" function and heterogeneity p-value with the

"mr_heterogeneity()" function. Following that, a "leave one out" analysis was

executed to assess the impact of particular SNPs on the assessment of causal effects.

All MR analysis were performed in R version 4.2.2 using the "TwoSampleMR"

package [26]. The Benjamini-Hochberg multiple testing was used to account for

multiple tests. Colocalization analysis was used to assess the possibility of two traits

sharing a shared causal variant, as previously stated [25, 27]. A posterior probability

for H4 (PH4) of more than 80% was considered significant colocalization evidence.

Mediation analysis

To evaluate the causal mediation effects, network MR with a product of

coefficients method was employed, as described by Yoshiji and others [9, 15]. In brief,

we estimated the effect of plasma protein levels on TL ($\beta_{\text{protein-to-TL}}$) and the effect of

TL on diseases ($\beta_{\text{TL-to-disease}}$), and then multiplied these values

($\beta_{\text{mediated}} = \beta_{\text{protein-to-TL}} \times \beta_{\text{TL-to-disease}}$). Subsequently, we divided β_{mediated} by β_{total}

($\beta_{\text{protein-to-disease}}$) to estimate the proportion mediated.

Single-cell RNA sequencing analysis

The GSE138266 [28] and GSE174072 [29] datasets were obtained from the

NCBI Gene Expression Omnibus (GEO) and analyzed using the R software.

GSE138266 includes 12 scRNA-seq datasets from cerebrospinal fluid (CSF) in 6

multiple sclerosis patients and 6 control groups. The raw data of the gene expression

matrix was taken from GEO and turned into a Seurat object for downstream

processing, as previously indicated [30]. In brief, doublets were detected using the

"scrub.scrub_doublets()" function in Scrublet package (v2.0.2) [31] and further

removed. The Harmony R package v1.0 was used for addressing batch effects after

normalizing the data with log transformation and scaling [32]. The "FindClusters"

function was used to cluster cells, which were then annotated according to the original

literature [28, 29]. Gene sets (PSMB4, PARP1, GDI2, MAX, GMPR2, ARPC1B,

ATOX1, and NUDT5) for each cell type were used for scoring, and cell scoring was

performed by the "AddModuleScore" function in Seurat (v4.2.0).

Results and discussion

Identification of causal plasma proteins to TL

First, we implemented two-sample MR to determine the causal effects of plasma

proteins on TL outcomes. For the purpose of this analysis, *cis*-acting protein

quantitative loci (*cis*-pQTLs, pQTLs that are present inside a 1 Mb region around the

gene body) from 4,907 proteins were utilized, reducing the probability of directing

horizontal pleiotropy [9,12,14]. Following the *cis*-pQTL search and data

harmonization, 1,428 proteins were evaluated in MR for their estimated causal effects

on TL (**Figure 1A**). The F-statistics for all of the examined proteins were all greater

than 10, minimizing the possibility of weak instrument bias significantly

(**Supplementary Table 1**). After applying the Benjamini-Hochberg multiple testing

correction (FDR<0.05) and filtering procedure (**Figure 1A**), MR revealed 34 causal

proteins, including 17 positive and 18 negative associations (**Figure 1B**). For example,

one standard deviation (SD) increase in genetically predicted GDI2 levels was

associated with decreased TL (odds ratios (OR)=0.84, 95% confidence intervals (CI)

0.80-0.87, *p*=2.08e-15). Similarly, a one standard deviation rise in genetically

predicted ARPC1B levels was linked to lower levels of TL (OR=0.88, 95%CI

0.85-0.93, *p*=7.78e-07). Higher genetically predicted levels of NUDT5

(OR[95%CI]=1.12[1.06,1.18]; *p*=3.12e-05) and PARP1 (OR[95%CI]=1.88[1.72,

2.06]; *p*=1.61e-44) have been associated with increased levels of TL. The MR-Steiger

test was used to investigate potential bias from reverse causation, which supported a

causal direction of these 34 plasma protein levels influencing TL outcomes
(**Supplemental Table 1**). The 18 proteins found to be negatively linked to TL were
involved in the proteasome core complex, NIK/NF-kappaB signaling, Wnt signaling
pathway, and interleukin-1-mediated signaling network (**Figure 1C**). Furthermore, 17
proteins positively related to TL were shown to be enriched in cellular response to
starvation, RNA helicase activity, mitochondrial DNA metabolic process, and
antifungal humoral response (p.adj<0.05) (**Figure 1C**). Colocalization analyses were
then performed to assess the likelihood that protein and TL share the same causal
variants rather than being shared accidentally due to LD associations (**Figure 1D-1E**).
Interestingly, 8 proteins (PSMB4, PARP1, GDI2, MAX, GMPR2, ARPC1B, ATOX1,
and NUDT5) were well colocalized with TL, with posterior probability greater than
80% for a shared signal. Two proteins (NRBP1 and BTN3A1) have a medium
posterior probability of more than 70%. The other 25 proteins had a poor
colocalization posterior probability with TL, indicating that these interactions may be
impacted by LD.

To validate the assumption of a lack of directional pleiotropy, which can
reintroduce confounding, we utilized the PhenoScanner
(http://www.phenoscanner.medschl.cam.ac.uk/) databases to find out whether the
cis-pQTLs for 8 proteins were associated with any traits or diseases at the
genome-wide significant threshold of p<5e-08. Except for MAX and GMPR2, no
genome-wide significant association was detected for six proteins (PSMB4, PARP1,
GDI2, ARPC1B, ATOX1, and NUDT5). The deCODE study's lead *cis*-pQTL for
MAX (rs8181938) and GMPR2 (rs34354104) were associated with body-related traits
(termed as sub-associations), such as height, forced vital capacity, mean corpuscular
hemoglobin, and mean corpuscular volume, among others (**Supplementary Table 1**);
yet, since *cis*-acting protein quantitative loci were utilized in our study, these
associations may represent a case of vertical pleiotropy, minimizing the probability of
directional pleiotropy. Indeed, when employing *cis*-pQTL for MAX (rs8181938) and
GMPR2 (rs34354104) from the deCODE study as exposure and these sub-association
as outcomes, MR analysis indicated that both MAX and GMPR2 levels were

supposed to affect these sub-associations with no reverse causation ($p<4.2$e-08,

MR-Steiger test), suggesting that these sub-associations may be a case of vertical

pleiotropy, which does not bias MR interpretation (**Supplemental Table 1**).

To determine whether the 8 causative proteins had any cell type-specific

enrichment in whole blood leukocytes, we performed scRNA-seq analysis from GEO

(GSE174072) [29], which included 62,164 cells from 12 healthy individuals (**Figure**

1F). 14 cell types were annotated based on the metadata of cells in the origin paper

[29]. Subsequently, we compared module scores across cell populations to uncover a

probable cell population linked to these 8 causative proteins (**Figure 1G**). The module

score of proliferating lymphocytes, dendritic cells (DCs), and plasmacytoid DCs was

found to be considerably higher than the other cell populations (Mann-Whitney U test,

$p<0.001$), implying that these cell types may be responsible for the local production of

the 8 proteins.

Mediation effect of proteins on 8 diseases via TL

Previous study has demonstrated that TL has a causative effect on various

diseases, including an increased risk of melanoma, prostate cancer, thyroid cancer,

uterine fibroid, multiple sclerosis, and idiopathic pulmonary fibrosis with each

standard deviation increase in TL [8]. In contrast, each standard deviation increase in

TL was related to a lower risk of coronary artery disease and hypothyroidism [8].

However, the mechanisms behind these associations were primarily unresolved. To

investigate this, two hypotheses have been proposed: (1) TL may participate in protein

mediation of diseases; and (2) proteins mediate the influence of TL on diseases

(discussed below). To test the first hypothesis, a two-sample MR was used to

investigate the causal effect of 34 proteins related to TL on 8 diseases (**Supplemental**

Table 1). Following MR analysis, sensitivity analysis identified 33 substantially

associated associations (two associations had been removed due to failure to pass

leave-one-out analysis) (**Figure 1H**). Except for BTN3A1, which appears to be shared

as a causative variant with prostate cancer (PH4=0.807), there is no strong

colocalization evidence for these significant associations. Interestingly, genetically

higher levels of PARP1 were related to an increased incidence of melanoma

(OR[95%CI]: 4.37[1.96, 9.71]; p=0.00029), prostate cancer (OR[95%CI]: 1.43[1.14,

1.81]; p=0.0021), and multiple sclerosis (OR[95%CI]: 4.09[2.009, 8.34]; p=0.0001).

Furthermore, ATOX1 was found to be genetically linked to a decreased risk of

multiple sclerosis. Using sing-cell RNA sequencing of cerebrospinal fluid from

multiple sclerosis patients and control groups (GEO, GSE138266) [28], it was found

that PARP1 expression in B cells and plasma cells was higher in multiple sclerosis

patients than in control groups (p<0.05) (**Figure S2A-S2D**). In contrast, ATOX1

expression in mDCs was lower in the cerebrospinal fluid of multiple sclerosis patients

than in control groups (p=0.03). These findings suggest that PARP1 and ATOX1 may

represent potential therapeutic targets for multiple sclerosis.

Subsequently, we performed a mediation study utilizing the effect estimates from

two-step MR and the overall effect from primary MR to evaluate the indirect effect of

proteins on 8 diseases via TL (**Figure 1I**). There were a total of 21 mediation

pairs revealed (**Supplemental Table 1**). For example, the proportion of PARP1's TL

mediation effect on melanoma, prostate cancer, and multiple sclerosis is 19.1%,

53.2%, and 26.6%, respectively. Similarly, with values of 11%, 20.4%, and 25.6%, TL

appears to mediate the effect of GDI2 on hypothyroidism, prostate cancer, and uterine

fibroids, respectively. The indirect effect of VAT1 on IPF risk via TL accounts for

32% of the total. Similarly, the proportion of TMEM106A's mediation effect on IPF

via TL is approximately one-quarter of the entire effect (28%) (**Figure 1I**).

Identification of the causal protein affected by TL

Following that, we used two-sample MR to quantify the effect of TL on

circulating protein levels on a proteome-wide scale (**Figure 2A**). The F-statistic,

which measures the strength of the correlation between genetic variations and TL,

was 119.6, indicating that there was no evidence of instrument bias. Out of the 4,907

proteins examined (**Supplemental Table 1**), 40 were found to be influenced by TL

(FDR<0.05), suggesting that TL has a moderate effect on plasma protein levels. After

that, we performed heterogeneity test, directional pleiotropy test, and

reverse-causation test to keep only the proteins that had been significantly affected by

TL. We found no significant heterogeneity in 40 proteins (I^2 <50% for all). The

MR-Egger intercept test revealed no evidence of directed horizontal pleiotropy in 35

of the 40 proteins tested ($P_{\text{Egger intercept}}$>0.05). There was no evidence of reverse

causation using protein levels as the exposures and TL as the outcome. Importantly,

according to the leave-one-out analysis, these 35 associations were not driven by

outliers. Therefore, a total of 35 protein levels were identified as causal proteins

impacted by TL, with no apparent heterogeneity, directional pleiotropy, or reverse

causation (**Figure 2B-2C**). Among the 35 causal proteins, 24 positively proteins

related to TL were positively associated with antimicrobial humoral response

(*p*.adj=0.00035) and positive regulation of wound healing (*p*.adj=0.0038), while 11

negatively proteins associated with TL were negatively associated with cellular

protein metabolic process (*p*.adj=0.018) and negative regulation of IRE1-mediated

unfolded protein response (*p*.adj=0.018) (**Figure 2D**). Interestingly, among the 35

TL-driven proteins studied, higher levels of TL were shown to be related to higher

levels of plasma CD8A (OR[95%CI]: 1.25[1.15, 1.36]; *p*=1.15e-07) (**Figure 2C**).

Previous research has shown that the number of CD8+ T cells declines linearly with

age, which is consistent with this finding [33-34]. To figure out whether

the subpopulation of CD8+ T cells was influenced by TL, MR analysis was carried

out on 102 cell populations of CD8 T cells from a cohort of 3,757 Sardinians [23].

Interestingly, following multiple testing corrections (FDR<0.05), CD8+ Natural Killer

T cells, Naive CD8+ T cells, and CD28+ CD45RA+ CD8+ T cells were essentially

affected by TL (**Figure 2E**). For these causality associations, MR analyses using the

weighted median, weighted mode, and MR-Egger slope approaches produced

directionally consistent results, as accomplished by the inverse variance weighted

method (**Supplemental Table 1**).

Causal effect of TL-driven proteins on 8 diseases

To test the second hypothesis, that proteins mediate the impact of TL on diseases,

a two-sample MR was initially performed to evaluate the causal effect of 35

TL-driven proteins on 8 diseases. Following the *cis*-pQTL search of 35 proteins and

data harmonization, 27 proteins were examined in the MR analysis. After MR analysis

and procedure filtering, no statistical significance was observed for 27 proteins on

diseases on a level of Benjamini-Hochberg multiple testing correction. However, 4

associations were discovered at the nominally significant (uncorrected $p<0.05$) level,

as validated by sensitivity and leave-one-out analysis (**Figure 2F**). It was discovered

that increasing blood ST3GAL6 expression by one SD was related to an increased

incidence of hypothyroidism (OR: 1.058; 95%CI: 1.015-1.103; $p=0.0076$). Per 1-SD

rise in blood SPOCK3 and ELANE expression, the incidence of multiple sclerosis

was reduced, with ORs (95%CI) of 0.79 (95%CI: 0.67-0.94; $p=0.0092$) and 0.502

(95%CI: 0.268-0.938, $p=0.030$), respectively. Furthermore, each 1-SD increase in

blood ST3GAL6 expression was linked to a lower incidence of hypothyroidism (OR:

1.058; 95%CI: 1.015-1.103; $p=0.0075$). However, there was no evidence that these 4

TL-driven proteins mediated the effect of TL on individual diseases due to the

opposite direction of the total effect ($\beta_{\text{TL-to-disease}}$) with the mediated effect

($\beta_{\text{TL-to-protein}} \times \beta_{\text{protein-to-disease}}$) (**Supplemental Table 1**).

Overall, we conducted a large-scale MR investigation that sought underlying

mechanisms that link plasma proteins, TL, and 8 diseases (**Figure 3**). PSMB4, PARP1,

GDI2, MAX, GMPR2, ARPC1B, ATOX1, and NUDT5 were found to be genetically

linked to TL. Of interest, 21 pairs have revealed that the length of telomeres mediates

the causative effect of circulating proteins on diseases. These findings provide

insights into telomere biology and prioritize the identified proteins as potential

intervention targets for the disease. Future research with a larger and more distinct

genetic background should be used to validate these results.

Acknowledgments

The authors thank all of the researchers from the related genetic consortia and GWAS

for making the data available to the public.

Disclosure

All the authors declared no competing interests.

Contributions

SF: study conception and design, data curation and analysis, and writing and

reviewing of the manuscript. MJ: data curation, as well as manuscript preparation and

review.

References

Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. *Proc Natl Acad Sci U S A* 1992;89:10114-8. doi:10.1073/pnas.89.21.10114

Demanelis K, Jasmine F, Chen LS, et al. Determinants of telomere length across human tissues. *Science* 2020;369. doi:10.1126/science.aaz6876

Chakravarti D, LaBella KA, DePinho RA. Telomeres: history, health, and hallmarks of aging. *Cell* 2021;184:306-22. doi:10.1016/j.cell.2020.12.028

Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. *Proc Natl Acad Sci U S A* 2007;104:7552-7. doi:10.1073/pnas.0701009104

Duckworth A, Gibbons MA, Allen RJ, et al. Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study. *Lancet Respir Med* 2021;9:285-94. doi:10.1016/S2213-2600(20)30364-7

Li C, Stoma S, Lotta LA, et al. Genome-wide Association Analysis in Humans Links Nucleotide Metabolism to Leukocyte Telomere Length. *Am J Hum Genet* 2020;106:389-404. doi:10.1016/j.ajhg.2020.02.006

Taub MA, Conomos MP, Keener R, et al. Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed. *Cell Genomics* 2022;2. doi:10.1016/j.xgen.2021.100084

Codd V, Wang Q, Allara E, et al. Polygenic basis and biomedical consequences of telomere length variation. *Nat Genet* 2021;53:1425-33. doi:10.1038/s41588-021-00944-6

Yoshiji S, Butler-Laporte G, Lu T, et al. Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. *Nat Metab* 2023;5:248-64. doi:10.1038/s42255-023-00742-w

Sekula P, Del Greco FM, Pattaro C, et al. Mendelian randomization as an approach to assess causality using observational data. *J Am Soc Nephrol* 2016;27:3253-65. doi:10.1681/ASN.2016010098

11 Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting

of observational studies in epidemiology using mendelian randomisation

(STROBE-MR): Explanation and elaboration. *BMJ* 2021;375.

doi:10.1136/bmj.n2233

12 Nakanishi T, Cerani A, Forgetta V, et al. Genetically increased circulating FUT3

level leads to reduced risk of idiopathic pulmonary fibrosis: A Mendelian

randomisation study. *Eur Respir J* 2022;59. doi:10.1183/13993003.03979-2020

13 Chen L, Peters JE, Prins B, et al. Systematic Mendelian randomization using the

human plasma proteome to discover potential therapeutic targets for stroke. *Nat*

Commun 2022;13:1-14. doi:10.1038/s41467-022-33675-1

14 Mazidi M, Wright N, Yao P, et al. Plasma Proteomics to Identify Drug Targets for

Ischemic Heart Disease. *J Am Coll Cardiol* 2023;82:1906-20.

doi:10.1016/j.jacc.2023.09.804

15 Yoshiji S, Lu TY, Butler-Laporte G, et al. COL6A3-derived endotrophin mediates

the effect of obesity on coronary artery disease:an integrative proteogenomics analysis.

medRxiv 2023. doi: 10.1101/2023.04.19.23288706.

16 Ferkingstad E, Sulem P, Atlason BA, et al. Large-scale integration of the plasma

proteome with genetics and disease. *Nat Genet* 2021;53:1712-21.

doi:10.1038/s41588-021-00978-w.

17 Wang A, Shen J, Rodriguez AA, et al. Characterizing prostate cancer risk through

multi-ancestry genome-wide discovery of 187 novel risk variants. *Nat Genet*

Published Online First: 2023. doi:10.1038/s41588-023-01534-4

18 Gallagher CS, Mäkinen N, Harris HR, et al. Genome-wide association and

epidemiological analyses reveal common genetic origins between uterine

leiomyomata and endometriosis. *Nat Commun* 2019;10:1-11.

doi:10.1038/s41467-019-12536-4

19 Mathieu S, Briend M, Abner E, et al. Genetic association and Mendelian

randomization for hypothyroidism highlight immune molecular mechanisms. *iScience*

2022;25. doi:10.1016/j.isci.2022.104992

20 Van Der Harst P, Verweij N. Identification of 64 novel genetic loci provides an

expanded view on the genetic architecture of coronary artery disease. *Circ Res*

2018;122:433-43. doi:10.1161/CIRCRESAHA.117.312086

21 Rashkin SR, Graff RE, Kachuri L, et al. Pan-cancer study detects genetic risk

variants and shared genetic basis in two large cohorts. *Nat Commun* 2020;11.

doi:10.1038/s41467-020-18246-6

22 International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic

map implicates peripheral immune cells and microglia in susceptibility. *Science*

2019;365:eaav7188. doi: 10.1126/science.aav7188

23 Orrù V, Steri M, Sidore C, et al. Complex genetic signatures in immune cells

underlie autoimmunity and inform therapy. *Nat Genet* 2020;52:1036-45.

doi:10.1038/s41588-020-0684-4

24 Allen RJ, Stockwell A, Oldham JM, et al. Genome-wide association study across

five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis.

Thorax 2022;77:829-33. doi:10.1136/thoraxjnl-2021-218577

25 Li SF & Gong MJ. Therapeutic targets for haemorrhoidal disease: proteome-wide

Mendelian randomisation and colocalization analyses. medRxiv 2023.

doi:10.1101/2023.06.19.2329137.

26 Hemani G, Zheng J, Elsworth B, et al. The MR-base platform supports systematic

causal inference across the human phenome. *Elife* 2018;7:1-29.

doi:10.7554/eLife.34408

27 Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian Test for

Colocalisation between Pairs of Genetic Association Studies Using Summary

Statistics. *PLoS Genet* 2014;10. doi:10.1371/journal.pgen.1004383

28 Schafflick D, Xu CA, Hartlehnert M, et al. Integrated single cell analysis of blood

and cerebrospinal fluid leukocytes in multiple sclerosis. *Nat Commun* 2020;11:1-14.

doi:10.1038/s41467-019-14118-w

29 Wilk AJ, Lee MJ, Wei B, et al. Multi-omic profiling reveals widespread

dysregulation of innate immunity and hematopoiesis in COVID-19. *J Exp Med*

2021;218. doi:10.1084/jem.20210582

30 Li SF & Gong MJ. Integrative single-cell analysis of epigenomic and

transcriptomic states in patients with systemic sclerosis-associated interstitial lung

disease. medRxiv 2023. doi: 10.1101/2023.09.05.23294979.

31   Wolock SL, Lopez R, Klein AM. Scrublet: Computational Identification of Cell

Doublets in Single-Cell Transcriptomic Data. *Cell Syst* 2019;8:281-291.e9.

doi:10.1016/j.cels.2018.11.005

32   Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of

single-cell   data   with   harmony.   *Nat   Methods*   2019;16:1289-96.

doi:10.1038/s41592-019-0619-0

33   Shin MS, Yim K, Moon K, et al. Dissecting alterations in human CD8+ T cells

with aging by high-dimensional single cell mass cytometry. *Clin Immunol*

2019;200:24-30. doi:10.1016/j.clim.2019.01.005

34   Kumar B V., Connors TJ, Farber DL. Human T Cell Development, Localization,

and   Function   throughout   Life.   *Immunity*   2018;48:202-13.

doi:10.1016/j.immuni.2018.01.007

Figure Legends

Figure 1. The causal effect of plasma proteins on TL. (**A**) Design overview for the

investigation of the causal effect of proteins on TL. FDR, false discovery rate; LOOA,

leave-one-out analysis. (**B**) Volcano plots of MR results for the causal effect of plasma

proteins on TL levels. Labeled proteins are 34 proteins examined in the primary

analysis with a significant FDR-corrected *p*-value<0.05. (**C**) Biological function

enrichment analysis for the 17 positively and 18 negatively associated TL proteins. (**D**)

A boxplot illustrating the results of the co-localization analysis for the 34 proteins

described in (B). Eight proteins with high colocalization evidence (PH4>0.8) were

labeled. (**E**) The locus-compare scatter plot for the identified proteins' association

with TL. The locus-compare scatter plot compares the results of the protein

quantitative trait loci (pQTL) and TL genome-wide association study (GWAS),

indicating whether the two traits shared the same genetic variants. (**F**) UMAP

embeddings of scRNA-seq profiles (GSE174072) from 62,164 blood leukocytes in 12

healthy donors. (**G**) Module scores of gene sets (PSMB4, PARP1, GDI2, MAX,

GMPR2, ARPC1B, ATOX1, and NUDT5) in each cell type. The *p*-value was obtained

by the Mann-Whitney U test. (**H**) Causal effects of the selected proteins on diseases

using MR analysis. The dots are the causal estimates on the OR scale, and the

whiskers represent the 95% confidence intervals (CI) for these ORs. OR, odd ratios. (**I**)

Mediation effects of selected proteins on diseases via TL. Mediation analyses were

used to quantify the effects of 34 proteins on 8 diseases outcomes via TL. The global

mediation-pairs were provided in Supplemental Table 1. TL, telomere length.

Figure 2. The causal effect of TL on proteins. (**A**) Design overview for the

investigation of the causal effect of TL on proteins. FDR, false discovery rate; LOOA,

leave-one-out analysis. (**B**) Volcano plots of MR results for the causal effect of TL on

plasma proteins. Labeled proteins are 35 proteins examined in primary analysis with a

significant FDR-corrected *p*-value<0.05. (**C**) Scatter plot for the causal effect of TL

on the selected protein levels. (**D**) Enrichment analysis of biological functions for the

24 positively and 11 negatively influenced proteins by TL. (**E**) Causal effects of TL on

13 CD8+ T subpopulations. (**F**) Causal effects of the selected proteins on diseases.

The dots are the causal estimates on the OR scale, and the whiskers represent the 95%

confidence intervals for these ORs. OR, odd ratios. TL, telomere length.

Figure 3. Schematic representation of the results we obtained in the study.

Figure S1 Single-cell transcriptomic atlas of cell types in the cerebrospinal fluid

of multiple sclerosis patients and controls. (**A**) UMAP visualization of 33,797 cells

in cerebrospinal fluid from controls (n=6) and patients with multiple sclerosis (n=6).

(**B**) A dot-plot depicting the expression of marker genes in each cell type. (**C**) Barplots

showing the proportion of cell types in each sample. (**D**) The differential expression

levels of PARP1 and ATOX1 between controls and MS samples. CSF, cerebrospinal

fluid; MS, multiple sclerosis.

Supplementary Table 1. The detailed GWAS information used in our

investigation, as well as the summary statistics obtained in this study.

Fig 1

Fig 2